The stock trading graph of Johnson & Johnson is seen on a smartphone screen.
Johnson & Johnson on Tuesday reported fourth-quarter earnings and revenue that narrowly edged out Wall Street's expectations as sales in the company's pharmaceutical and medical devices businesses surged.
J&J also provided full-year guidance for 2024, forecasting sales of $87.8 billion to $88.6 billion and adjusted earnings of $10.55 to $10.75 per share.
The pharmaceutical giant reported net income of $4.13 billion, or $1.70 per share during the quarter.
J&J is now zeroing in on its pharmaceutical and medical devices divisions to drive growth.
Persons:
Johnson, J
Organizations:
LSEG